MRNA at a glance
The past year
Chart+769.1% $215.27, close Nov 16
- From the highest close
- −20.0%
- Vs the 200-day average
- +121.3%
Short interest
History33.2M shares
- Of shares outstanding
- 8.20%
- Since the last report
- +1.8%
- Days to cover
- 1.8 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 10 – Nov 16
Top investors
Funds1 of 37 funds hold it
- Ray Dalio
- 0.0%
- Latest 13F filings
- 0 added · 1 cut
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
MRNA price history
Loading recent earnings…
Investment thesis
What must happen next
Moderna’s mRNA platform must produce commercially adopted products beyond the pandemic franchise, proving that shared mRNA design and manufacturing know-how can be reused across diseases rather than being a one-product success.HoldingMateriality: High
The company describes itself as advancing a technology platform to reimagine how medicines are made. If the platform is repeatable, today’s losses can be investment in future franchises; if not, the pipeline spend destroys the COVID windfall.
Watch: Late-stage non-COVID mRNA programs fail efficacy or safety endpoints, showing the platform does not generalize.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company describes itself as advancing a technology platform to reimagine how medicines are made.
Open source ↗Seasonal respiratory vaccines must become a durable, priced commercial channel for Moderna, not merely a lower-volume replacement for pandemic purchasing.HoldingMateriality: High
FY2025 annual GAAP gross profit was $1.076 billion on $1.944 billion of revenue, indicating positive product economics remain. Revenue that returns at poor price, mix, or utilization will not rebuild the earnings power implied by the platform story.
Watch: CDC/ACIP or international advisory bodies narrow respiratory vaccine eligibility, reducing the recurring addressable market.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP gross profit was $1.076 billion on $1.944 billion of revenue, indicating positive product economics remain.
Open source ↗Moderna has to make its R&D, manufacturing, and commercial infrastructure flexible enough for post-pandemic demand; otherwise the platform’s scientific optionality will be overwhelmed by fixed operating costs.HoldingMateriality: Medium
FY2025 annual GAAP operating loss was $3.074 billion, improved from a $4.239 billion loss in FY2023. A smaller but high-potential product base can still create value if losses narrow; persistent fixed-cost drag would force the company to cut the pipeline or raise capital.
Watch: Large Phase 3 programs require sustained spending before commercial proof arrives.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP operating loss was $3.074 billion, improved from a $4.239 billion loss in FY2023.
Open source ↗Management must pace pipeline investment so Moderna reaches value-inflecting approvals or partnerships before operating cash burn forces dilutive financing.HoldingMateriality: Medium
FY2025 annual GAAP operating cash flow was negative $1.873 billion, better than negative $3.004 billion in FY2024 and negative $3.118 billion in FY2023. Cash runway determines whether shareholders own the pipeline upside or fund it through dilution after the stock has already absorbed the revenue cliff.
Watch: Clinical failures force Moderna to fund additional large trials without partner support.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
FY2025 annual GAAP operating cash flow was negative $1.873 billion, better than negative $3.004 billion in FY2024 and negative $3.118.
Open source ↗The platform advantage depends on retaining specialized mRNA, clinical, regulatory, and manufacturing talent that can reuse knowledge across programs; excessive cuts or attrition would slow pipeline conversion.HoldingMateriality: Medium
Moderna reported approximately 4,700 full-time employees in 18 countries as of December 31, 2025. If the human-capital base is preserved, Moderna can compound learning across programs; if it is hollowed out, cost cuts may improve near-term losses while impairing the core asset.
Watch: Key scientists, manufacturing leaders, or regulatory executives leave for BioNTech, large pharma, or other biotech competitors.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Moderna reported approximately 4,700 full-time employees in 18 countries as of December 31, 2025.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Moderna’s mRNA platform must produce commercially adopted products beyond the pandemic franchise, proving that shared mRNA design and manufacturing know-how can be reused across diseases rather than being a one-product success. If the platform is repeatable, today’s losses can be investment in future franchises; if not, the pipeline spend destroys the COVID windfall.
Seasonal respiratory vaccines must become a durable, priced commercial channel for Moderna, not merely a lower-volume replacement for pandemic purchasing. Revenue that returns at poor price, mix, or utilization will not rebuild the earnings power implied by the platform story.
Moderna has to make its R&D, manufacturing, and commercial infrastructure flexible enough for post-pandemic demand; otherwise the platform’s scientific optionality will be overwhelmed by fixed operating costs. A smaller but high-potential product base can still create value if losses narrow; persistent fixed-cost drag would force the company to cut the pipeline or raise capital.
Management must pace pipeline investment so Moderna reaches value-inflecting approvals or partnerships before operating cash burn forces dilutive financing. Cash runway determines whether shareholders own the pipeline upside or fund it through dilution after the stock has already absorbed the revenue cliff.
The platform advantage depends on retaining specialized mRNA, clinical, regulatory, and manufacturing talent that can reuse knowledge across programs; excessive cuts or attrition would slow pipeline conversion. If the human-capital base is preserved, Moderna can compound learning across programs; if it is hollowed out, cost cuts may improve near-term losses while impairing the core asset.
All standing thesis claims
Original report summary
mRNA becomes a repeatable multi-product engine, but the stock fails if COVID-era cash is consumed before non-COVID products scale.
Bull case and bear case
Bull case and bear case for Moderna
Where the evidence on Moderna stands: Holding on the latest evidence (Nov 17, 2026). Of its 5 thesis points, 5 holding.
Bull case: what the evidence supports
Moderna’s mRNA platform must produce commercially adopted products beyond the pandemic franchise, proving that shared mRNA design and manufacturing know-how can be reused across diseases rather than being a one-product success.
Seasonal respiratory vaccines must become a durable, priced commercial channel for Moderna, not merely a lower-volume replacement for pandemic purchasing.
Moderna has to make its R&D, manufacturing, and commercial infrastructure flexible enough for post-pandemic demand; otherwise the platform’s scientific optionality will be overwhelmed by fixed operating costs.
Management must pace pipeline investment so Moderna reaches value-inflecting approvals or partnerships before operating cash burn forces dilutive financing.
The platform advantage depends on retaining specialized mRNA, clinical, regulatory, and manufacturing talent that can reuse knowledge across programs; excessive cuts or attrition would slow pipeline conversion.
Bear case: what would count against it
Late-stage non-COVID mRNA programs fail efficacy or safety endpoints, showing the platform does not generalize.
CDC/ACIP or international advisory bodies narrow respiratory vaccine eligibility, reducing the recurring addressable market.
Large Phase 3 programs require sustained spending before commercial proof arrives.
Company research
Research on Moderna
- Reporting · Why Is Moderna, Inc. (NASDAQ: MRNA) Stock Up 569% This Year?
A Phase 3 melanoma result turned oncology into a credible business line, but the rally still depends on data, approval and individualized manufacturing.
Thesis-Break Engine
What has broken in Moderna’s thesis
Each break OptimistFi flagged on Moderna, dated — with what has historically followed the same kind of break across the market, not a forecast for Moderna.
- Analyst downgradecondition set before this filing
Across all companies, this kind of break has happened 12,641 times before. Those stocks trailed comparable companies by a median of 1% over the next six months, and 33% of them trailed it by 10 points or more.
- CEO / officer changecondition set before this filing
Across all companies, this kind of break has happened 16,849 times before. Those stocks trailed comparable companies by a median of 2% over the next six months, and 38% of them trailed it by 10 points or more.
- Insider-selling clustercondition set before this filing
Across all companies, this kind of break has happened 9,137 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 30% of them trailed it by 10 points or more.
Several kinds of break have stacked on Moderna at once. A cluster is a stronger read than any one signal alone.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Moderna filed an SEC 8-K on 2026-11-16: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Moderna filed an SEC 8-K on 2026-11-13: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Moderna filed an SEC 8-K on 2026-11-06: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Late-stage non-COVID mRNA programs fail efficacy or safety endpoints, showing the platform does not generalize.
- CDC/ACIP or international advisory bodies narrow respiratory vaccine eligibility, reducing the recurring addressable market.
- Large Phase 3 programs require sustained spending before commercial proof arrives.
- Clinical failures force Moderna to fund additional large trials without partner support.
- Key scientists, manufacturing leaders, or regulatory executives leave for BioNTech, large pharma, or other biotech competitors.
MRNA news
Loading headlines…
Financial statements
MRNA income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
MRNA: quick answers
- When does Moderna (MRNA) report earnings next?
- Moderna's next results are projected for February 12, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 6, 2026. Earnings calendar
- What is MRNA's short interest?
- As of October 30, 2026, 33.2M MRNA shares were sold short, 8.20% of its shares outstanding, up 1.8% from the count before. At the stock's average daily volume that is 1.8 days to cover. FINRA publishes the count twice a month. MRNA short interest history
- Which well-known investors own MRNA?
- 1 of the 37 well-known funds tracked here reported MRNA shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios
MRNA in well-known investors’ portfolios
1 of 37 funds reported MRNA shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Ray DalioBridgewater Associates | 0.00% | $807K | −84.6% | Q2 2026 |

